What's Driving Erasca (ERAS)'s Nearly 355% YTD Return [Yahoo! Finance]
Erasca, Inc. (ERAS)
Company Research
Source: Yahoo! Finance
Erasca, Inc. (NASDAQ:ERAS) to $25 from $24 and maintained an Overweight rating. This upward price revision is based on the firm's model adjustments within the SMID-cap biotechnology group. Back on March 13, Stifel reaffirmed a Buy rating on Erasca, Inc. (NASDAQ:ERAS) with a price target of $20. This comes after the company's Q4 results, in which it reported a net loss of $29.1 million for the quarter and $124.6 million for 2025. Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar adriaticfoto/Shutterstock.com Additionally, Erasca, Inc. (NASDAQ:ERAS) maintained cash and cash equivalents of $341.8 million as of the year-end. What bolsters the case for the company is its nearly $434 million in pro forma cash to fund operations in the latter half of 2028. Stifel highlights that the cash runway stretches past key ERAS-0015 clinical catalysts planned for the first half of this year and the next. On the same day, H.C. Wainwright el
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Erasca (ERAS) Climbs 390% YTD on ‘Best-in-Class' Potential of Cancer Treatment [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) Among the Best Performing Stocks of Q1 2026 to Watch for Q2 [Yahoo! Finance]Yahoo! Finance
- Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't [Yahoo! Finance]Yahoo! Finance
- Assessing Erasca (ERAS) Valuation After ERAS-0015 Licensing Win And Data Anticipation [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) Adds 13%; Soars 310% YTD [Yahoo! Finance]Yahoo! Finance
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 4/15/26 - Form 144/A
- 4/15/26 - Form 144
- 4/3/26 - Form 4
- ERAS's page on the SEC website